Trial Failure Forces Major Restructuring at Theravance Biopharma

Theravance Biopharma is restructuring its research and development operations and cutting about half of its workforce after its rare disease drug failed in a late-stage trial. The decision follows disappointing results from the Phase III CYPRESS Study (NCT05696717) evaluating ampreloxetine for neurogenic orthostatic hypotension caused by multiple system atrophy.

The drug did not improve the Orthostatic Hypotension Symptom Assessment score after eight weeks, missing the study’s primary endpoint. Secondary outcomes showed similar results, although biological activity was observed through changes in blood pressure, heart rate, and norepinephrine levels. The treatment was generally well tolerated.

Following the setback, the company will discontinue development of ampreloxetine and close its R&D division. The restructuring will affect around 50% of employees and is expected to reduce annual operating expenses by about $70m.

Future revenue will rely mainly on partnerships involving Yupelri (revefenacin) and Trelegy (fluticasone furoate/umeclidinium/vilanterol) for chronic obstructive pulmonary disease.

04-03-2026